Lupin Ltd. is Rated Buy by MarketsMOJO

Current Rating and Its Significance

MarketsMOJO’s 'Buy' rating for Lupin Ltd. indicates a positive outlook on the stock, suggesting it is a favourable investment opportunity based on a comprehensive evaluation of multiple factors. This rating reflects a strong confidence in the company’s ability to deliver value to shareholders, balancing growth prospects with reasonable valuation and financial health. Investors should understand that a 'Buy' rating implies the stock is expected to outperform the broader market or its sector peers over the medium term.

Quality Assessment

As of 11 March 2026, Lupin Ltd. maintains a good quality grade. The company’s operational performance demonstrates resilience and consistent growth. Notably, Lupin has reported positive results for the last three consecutive quarters, underscoring its stable earnings momentum. The Return on Capital Employed (ROCE) for the half-year period stands at an impressive 22.22%, signalling efficient utilisation of capital to generate profits. Furthermore, the company’s Return on Equity (ROE) is a robust 22%, reflecting strong profitability relative to shareholder equity.

Valuation Perspective

The valuation grade for Lupin Ltd. is currently assessed as attractive. The stock trades at a Price to Book (P/B) ratio of 5.5, which, while elevated, is considered reasonable given the company’s growth trajectory and profitability metrics. Importantly, Lupin’s valuation is at a discount compared to its peers’ historical averages, offering investors a favourable entry point. The Price/Earnings to Growth (PEG) ratio is notably low at 0.3, indicating that the stock’s price growth is well supported by its earnings growth, which is a positive sign for value-conscious investors.

Financial Trend and Performance

Financially, Lupin Ltd. exhibits a positive trend. The company’s net sales have grown at an annualised rate of 11.42%, while operating profit has surged by 33.60%, highlighting strong operational leverage. The latest quarterly figures reveal net sales reaching a record high of ₹7,167.52 crores, and Profit Before Tax excluding other income (PBT LESS OI) has grown by 43.6% compared to the previous four-quarter average, standing at ₹1,833.91 crores. Additionally, Lupin maintains a low average Debt to Equity ratio of 0.10 times, indicating prudent financial management and limited leverage risk.

Technical Outlook

From a technical standpoint, Lupin Ltd. is rated as bullish. The stock has demonstrated consistent upward momentum, with returns of +0.53% on the latest trading day and gains of +18.81% over the past year as of 11 March 2026. Shorter-term performance is also strong, with a 3-month return of +13.12% and a 6-month return of +18.25%. This positive price action is supported by healthy institutional interest, with institutional holdings at 47.08%, reflecting confidence from sophisticated investors who typically conduct thorough fundamental analysis.

Implications for Investors

For investors, the 'Buy' rating on Lupin Ltd. suggests that the stock is well-positioned to deliver attractive returns, supported by solid fundamentals, reasonable valuation, positive financial trends, and favourable technical signals. The company’s strong profitability metrics and growth in sales and earnings provide a sound basis for confidence. Meanwhile, the attractive valuation relative to peers and the broader sector offers a margin of safety. The bullish technical indicators further reinforce the stock’s potential for continued appreciation.

Sector and Market Context

Lupin operates within the Pharmaceuticals & Biotechnology sector, a space characterised by innovation, regulatory challenges, and steady demand. The company’s midcap status places it in a dynamic growth category, often offering more upside potential than large-cap peers while maintaining a degree of stability. The current Mojo Score of 78.0, down slightly from 81.0 on 16 February 2026, still reflects a strong overall assessment, supporting the 'Buy' recommendation.

Summary of Key Metrics as of 11 March 2026

Lupin Ltd.’s financial health is underscored by a low debt burden, with an average Debt to Equity ratio of 0.10 times, which reduces financial risk and enhances flexibility. The company’s net sales growth of 11.42% annually and operating profit growth of 33.60% demonstrate strong operational performance. The recent quarterly results highlight record net sales of ₹7,167.52 crores and a significant increase in profit before tax, signalling robust earnings momentum. The Return on Capital Employed (ROCE) and Return on Equity (ROE) metrics, at 22.22% and 22% respectively, confirm efficient capital utilisation and shareholder value creation.

Valuation and Market Performance

Despite the strong growth, Lupin’s valuation remains attractive, trading at a P/B ratio of 5.5 and a PEG ratio of 0.3, indicating that the stock price is well supported by earnings growth. The stock’s performance over the past year, with an 18.81% return, outpaces many peers in the Pharmaceuticals & Biotechnology sector. Institutional investors hold a significant 47.08% stake, reflecting confidence from market participants with deep analytical resources.

Conclusion

In conclusion, Lupin Ltd.’s current 'Buy' rating by MarketsMOJO is grounded in a balanced assessment of quality, valuation, financial trends, and technical strength. The company’s solid fundamentals, attractive valuation, positive earnings trajectory, and bullish price momentum combine to make it a compelling investment option within the midcap pharmaceutical space. Investors seeking exposure to a well-managed, growth-oriented pharmaceutical company may find Lupin Ltd. a suitable addition to their portfolio, with the potential for sustained returns supported by strong institutional backing and operational excellence.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today